Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502245 | 0.87 | NPC1 (0.41) | DHODHMAOBNPC1RXFP1MAPT | |
| SCHEMBL3501284 | 0.79 | ALOX5AP (0.42) | DHODHMAOBALOX5APFEN1NPC1 | |
| SCHEMBL30540118 | 0.78 | KMO (0.47) | DHODHALOX5APFEN1NPC1KMO | |
| SCHEMBL19248543 | 0.78 | KMO (0.47) | DHODHALOX5APFEN1NPC1KMO | |
| SCHEMBL3502067 | 0.78 | NPC1 (0.63) | MAOBNPC1RXFP1MAPTRAB9A | |
| SCHEMBL4388622 | 0.77 | P4HA1 (0.58) | DHODHFEN1NPC1RXFP1KMO | |
| SCHEMBL22801096 | 0.77 | FYN (0.58) | MAOBNPC1RXFP1FYNHPGDS | |
| SCHEMBL12987550 | 0.76 | ESR1 (0.46) | DHODHALOX5APFEN1KMO | |
| SCHEMBL9607067 | 0.75 | DHODH (0.47) | DHODHMAOBALOX5APFEN1NPC1 | |
| SCHEMBL6313842 | 0.75 | SYK (0.43) | MAOBALOX5APFEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | BRS3, INSR, INSRR | DHODH 4852/4885MAOB 2828/4885ALOX5AP 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.